Latest Breaking News On - China medical system holdings ltd - Page 1 : vimarsana.com

China Medical System: New Drug Application of Desidustat Tablets Accepted in China – IT Business Net

Zydus gets China nod for kidney disease drug

Ahmedabad-based Zydus Lifesciences said on Tuesday that a new drug application for its oral drug Desidustat used in treating anaemia in chronic kidney disease (CKD) patients had been accepted by the National Medical Products Administration of China (NMPA). In 2020, CMS International Development and Management Ltd, a wholly-owned subsidiary of China Medical System Holdings Ltd obtained an exclusive license for the product from Zydus. CKD involves a gradual loss of functioning of kidneys and eventually leads to kidney failure.

China Medical System: New Drug Application of Desidustat Tablets Accepted in China

China Medical System: New Drug Application of Desidustat

SHENZHEN, CHINA, April 23, 2024 (GLOBE NEWSWIRE) Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney.

China Medical System: New Drug Application of Desidustat Tablets Accepted in China

Goldman Sachs just refreshed its Asia 'conviction list' of top stocks

Goldman Sachs' analysts said the risk/reward of one Chinese stock looked "increasingly attractive."

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia

CMS And Incyte Announce Collaboration And License Agreement For Povorcitinib In China And Southeast Asia